{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "Patient had anti-cardiolipin (aCL) antibodies detected: aCL IgM 26 MPL/mL and aCL IgA 60 APL/mL. Lupus anticoagulant (LAC), aCL IgG, and autoantibodies to B2-glycoprotein 1 were negative. Previous test results of antinuclear antibodies, antineutrophil cytoplasmic autoantibodies, and antibodies to double-stranded DNA were negative. Complement C3 and C4 levels were normal. Blood and sputum cultures were negative.",
        "clinical_data": {
          "labs": [
            {
              "test": "Anti-cardiolipin IgM",
              "value": "26",
              "unit": "MPL/mL",
              "flag": "abnormal"
            },
            {
              "test": "Anti-cardiolipin IgA",
              "value": "60",
              "unit": "APL/mL",
              "flag": "abnormal"
            },
            {
              "test": "Lupus anticoagulant",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Anti-cardiolipin IgG",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Autoantibodies to B2-glycoprotein 1",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Antinuclear antibodies",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Antineutrophil cytoplasmic autoantibodies",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Antibodies to double-stranded DNA",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Complement C3",
              "value": "normal",
              "flag": "normal"
            },
            {
              "test": "Complement C4",
              "value": "normal",
              "flag": "normal"
            },
            {
              "test": "Blood culture",
              "value": "negative",
              "flag": "normal"
            },
            {
              "test": "Sputum culture",
              "value": "negative",
              "flag": "normal"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Patient with advanced melanoma was treated with pembrolizumab and subsequently developed multiple organ failure due to Catastrophic Antiphospholipid Syndrome (CAPS). ",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C43",
              "label": "Melanoma",
              "status": "active"
            },
            {
              "code": "D68.69",
              "label": "Catastrophic antiphospholipid syndrome",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "C3876536",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "C43"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient with anti-cardiolipin (aCL) antibodies detected developed multiple organ failure due to Catastrophic Antiphospholipid Syndrome (CAPS) after treatment with pembrolizumab for advanced melanoma.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C3876536",
            "C0025202"
          ],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      }
    }
  ]
}